TONIX PHARMACEUTICALS HOLDING CORP. Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) had Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net of $1.16 million as of 2024-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Debt
us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet · last filed 2026-03-12
- 2024-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $1.16M.
- 2024-09-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $1.36M.
- 2024-06-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $1.57M.
- 2024-03-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $1.79M.
| Period end | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net |
|---|---|
| 2024-12-31 | $1.16M 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.36M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $1.57M 10-Q · filed 2024-08-16 |
| 2024-03-31 | $1.79M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $2.09M 10-K · filed 2025-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |